Adhera Therapeutics, Inc.
ATRX
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -12.34% | 36.15% | 107.60% | 140.00% | 129.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.34% | 36.15% | 107.60% | 140.00% | 129.86% |
| Operating Income | 12.34% | -36.15% | -107.60% | -140.00% | -129.86% |
| Income Before Tax | -30.12% | 48.85% | 51.21% | 66.72% | 33.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.12% | 48.85% | 51.21% | 66.72% | 33.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.12% | 48.85% | 51.21% | 66.72% | 33.24% |
| EBIT | 12.34% | -36.15% | -107.60% | -140.00% | -129.86% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 68.84% | 90.47% | 88.46% | 88.37% | 68.54% |
| Normalized Basic EPS | 58.17% | 87.77% | 86.95% | 90.10% | 65.36% |
| EPS Diluted | 66.51% | 89.58% | 88.45% | 88.36% | 68.53% |
| Normalized Diluted EPS | 55.82% | 86.92% | 86.95% | 90.10% | 65.36% |
| Average Basic Shares Outstanding | 134.55% | 269.98% | 261.06% | 214.40% | 157.47% |
| Average Diluted Shares Outstanding | 1,714.56% | 2,981.94% | 261.06% | 214.40% | 157.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
